Extended Data Fig. 1: PI3Kδ inhibition minimally decreases ALL peripheral disease burden.
From: Leukaemia hijacks a neural mechanism to invade the central nervous system
a, Representative haematoxylin and eosin (H&E)-stained histologic sections showing Nalm-6 disease burden in the femoral bone marrow and spleen of mice treated with vehicle or GS-649443, at matched time points. n = 6 mice per treatment group. b, Complete blood counts of vehicle- and GS-649443-treated mice, at matched time points. Paired two-tailed Student’s t-test, n = 5 mice per treatment group, P = 0.2158; ns, not significant. c, Fold changes in CNS versus systemic disease burden in vehicle- and GS-649443-treated Nalm-6-engrafted mice. Data are mean ± s.e.m.; ANOVA with Tukey’s multiple comparison test, n = 5 mice per treatment group, P = 0.0314. d, Representative histologic sections showing primary ALL disease burden in the femoral bone marrow and spleen of mice treated with vehicle or GS-649443 at matched time points. n = 5 mice per treatment group. e, Experimental plan for mice with primary ALL. f, Fold changes in CNS versus systemic disease burden in vehicle- and GS-649443-treated mice with primary ALL. Data are mean ± s.e.m.; ANOVA with Tukey, n = 5 mice per treatment group, P = 0.00128 (CNS versus bone marrow), P = 0.0098 (CNS versus spleen). g, Representative histologic sections showing RCH-ACV disease burden in the femoral bone marrow and spleen of mice treated with vehicle or GS-649443. n = 4 mice per treatment group. Arrowheads indicate RCH-ACV blasts. h, Kaplan–Meier survival curve for mice injected with RCH-ACV cells. Two-sided log rank Mantel-Cox, n = 5 mice per treatment group, P = 0.0067. i, Fold changes in CNS versus systemic disease burden in vehicle- and GS-649443-treated mice injected with RCH-ACV cells. Data are mean ± s.e.m.; ANOVA with Tukey, n = 4 mice per treatment group, P = 0.0244. Scale bars, 100 μm.
